Skip to main content

Advertisement

SpringerLink
Log in

Heparin: 100 years of pleiotropic effects

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Heparin is a glycosaminoglycan with anticoagulant properties and antiinflammatory effects. The discovery of heparin approaches its 100th year and its antiinflammatory properties still draws much attention and anticipation to new possibilities of use and the likelihood of developing heparin-like drugs that lacked the anticoagulation effects. It is known that heparins limit the embolization and the extension of the thrombus, although they do not promote its complete lysis in most cases. The complexity and pleiotropic characteristics of these glycosaminoglycans still challenge science, to the point in which approaches hitherto unusual appear repeatedly in the literature. New indications, accompanied by longtime consecrated others, dismantle the idea of an outdated medication and create high expectations for the near future. The objective of this review is to analyze the pleiotropic effects of heparin and its use in several diseases, highlighting its safety and effectiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lever R, Mulloy B, Page C (2012) Heparin—a century of progress. Springer, Berlin

    Book  Google Scholar 

  2. Best CH (1959) Preparation of heparin and its use in the first clinical cases. Circulation 19(1):79–86

    Article  CAS  PubMed  Google Scholar 

  3. Hirsh J, Siragusa S, Cosmi B, Ginsberg JS (1995) Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 74(1):360–363

    CAS  PubMed  Google Scholar 

  4. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P et al (1993) Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 153(13):1541–1546

    Article  CAS  PubMed  Google Scholar 

  5. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l’Embolie Pulmonaire. N Engl J Med 337(10):663–669

    Article  CAS  PubMed  Google Scholar 

  6. ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 84(8):1099–1103

    Article  Google Scholar 

  7. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D et al (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100(15):1593–1601

    Article  CAS  PubMed  Google Scholar 

  8. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354(14):1477–1488

    Article  CAS  PubMed  Google Scholar 

  9. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337(7):447–452

    Article  CAS  PubMed  Google Scholar 

  10. Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-Sendon J et al (2007) Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Eur Heart J 28(13):1566–1573

    Article  CAS  PubMed  Google Scholar 

  11. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW (2003) Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145(4):614–621

    Article  CAS  PubMed  Google Scholar 

  12. Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ et al (1991) Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 114(7):545–551

    Article  CAS  PubMed  Google Scholar 

  13. Palmer AJ, Schramm W, Kirchhof B, Bergemann R (1997) Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials. Haemostasis 27(2):65–74

    CAS  PubMed  Google Scholar 

  14. Page C (2013) Heparin and related drugs: beyond anticoagulant activity. ISRN Pharmacol 2013:910743

    Article  PubMed  PubMed Central  Google Scholar 

  15. Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e24S–e43S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162(16):1833–1840

    Article  CAS  PubMed  Google Scholar 

  18. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ceccarelli M, Bani D, Cinci L, Nistri S, Uliva C, Ragazzo E et al (2009) Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy. J Cell Mol Med 13(8b):2704–2712

    Article  PubMed  Google Scholar 

  20. Young E (2008) The anti-inflammatory effects of heparin and related compounds. Thromb Res 122(6):743–752

    Article  CAS  PubMed  Google Scholar 

  21. Bono F, Rigon P, Lamarche I, Savi P, Salel V, Herbert JM (1997) Heparin inhibits the binding of basic fibroblast growth factor to cultured human aortic smooth-muscle cells. Biochem J 326(Pt 3):661–668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Fredens K, Dahl R, Venge P (1991) In vitro studies of the interaction between heparin and eosinophil cationic protein. Allergy 46(1):27–29

    Article  CAS  PubMed  Google Scholar 

  23. Gilat D, Hershkoviz R, Mekori YA, Vlodavsky I, Lider O (1994) Regulation of adhesion of CD4+ T lymphocytes to intact or heparinase-treated subendothelial extracellular matrix by diffusible or anchored RANTES and MIP-1 beta. J Immunol. 153(11):4899–4906

    CAS  PubMed  Google Scholar 

  24. Page CP (1991) One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet 337(8743):717–720

    Article  CAS  PubMed  Google Scholar 

  25. Walsh RL, Dillon TJ, Scicchitano R, McLennan G (1991) Heparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin Sci (Lond). 81(3):341–346

    Article  CAS  PubMed  Google Scholar 

  26. Brown RA, Allegra L, Matera MG, Page CP, Cazzola M (2006) Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 19(6):419–424

    Article  CAS  PubMed  Google Scholar 

  27. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE (2005) Regulation of protein function by glycosaminoglycans—as exemplified by chemokines. Annu Rev Biochem 74:385–410

    Article  CAS  PubMed  Google Scholar 

  28. Lever R, Lo WT, Faraidoun M, Amin V, Brown RA, Gallagher J et al (2007) Size-fractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol 151(6):837–843

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P et al (2004) Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 173(9):5776–5785

    Article  CAS  PubMed  Google Scholar 

  30. Greinacher A (2011) Platelet activation by heparin. Blood 117(18):4686–4687

    Article  CAS  PubMed  Google Scholar 

  31. de Boer JD, Majoor CJ, van t Veer C, Bel EHD, van der Poll T (2012) Asthma and coagulation. Blood 119(14):3236–3244

    Article  PubMed  Google Scholar 

  32. Duong M, Cockcroft D, Boulet LP, Ahmed T, Iverson H, Atkinson DC et al (2008) The effect of IVX-0142, a heparin-derived hypersulfated disaccharide, on the allergic airway responses in asthma. Allergy 63(9):1195–1201

    Article  CAS  PubMed  Google Scholar 

  33. Stelmach I, Jerzynska J, Stelmach W, Majak P, Brzozowska A, Gorski P et al (2003) The effect of inhaled heparin on airway responsiveness to histamine and leukotriene D4. Allergy Asthma Proc 24(1):59–65

    CAS  PubMed  Google Scholar 

  34. Passowicz-Muszynska E, Jankowska R, Krasnowska M (2002) The effect of inhaled low molecular weight heparin on cell composition in bronchoalveolar lavage fluid and serum levels of soluble receptor IL-2 in bronchial asthma patients. Pol Merkur Lekarski 12(69):218–220

    PubMed  Google Scholar 

  35. Fal AM, Miecielica J, Krasnowska M, Medrala W, Kuryszko J, Malolepszy J (2001) Influence of long-term low molecular weight heparin nebulization on selected clinical parameters and course of allergic inflammation in patients with bronchial asthma. Pol Arch Med Wewn 106(6):1121–1129

    CAS  PubMed  Google Scholar 

  36. Tutluoglu B, Gurbuz N, Atis S, Abanozlu S, Ibis R, Kanik A (2001) Effects of heparin on hypertonic potassium chloride-induced bronchoconstriction. Ann Pharmacother 35(10):1161–1165

    Article  CAS  PubMed  Google Scholar 

  37. Vancheri C, Mastruzzo C, Armato F, Tomaselli V, Magri S, Pistorio MP et al (2001) Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol 108(5):703–708

    Article  CAS  PubMed  Google Scholar 

  38. Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H et al (2012) Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS ONE 7(6):e38629

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Qian Y, Xie H, Tian R, Yu K, Wang R (2014) Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Copd. 11(2):171–176

    Article  PubMed  Google Scholar 

  40. Shi X, Li H (2013) Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage. Exp Ther Med 5(5):1367–1370

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Falanga A (2004) The effect of anticoagulant drugs on cancer. J Thromb Haemost 2(8):1263–1265

    Article  CAS  PubMed  Google Scholar 

  42. Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275

    Article  PubMed  PubMed Central  Google Scholar 

  43. Khorana AA (2012) Cancer-associated thrombosis: updates and controversies. Hematol Am Soc Hematol Educ Program 2012:626–630

    Google Scholar 

  44. Lee AY (2012) Treatment of established thrombotic events in patients with cancer. Thromb Res 129(Suppl 1):S146–S153

    Article  CAS  PubMed  Google Scholar 

  45. Mandala M, Falanga A, Roila F (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 22(Suppl 6):vi85–vi92

    PubMed  Google Scholar 

  46. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C et al (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 74(1):38–45

    Article  CAS  PubMed  Google Scholar 

  47. Smorenburg SM, Hettiarachchi RJ, Vink R, Buller HR (1999) The effects of unfractionated heparin on survival in patients with malignancy—a systematic review. Thromb Haemost 82(6):1600–1604

    CAS  PubMed  Google Scholar 

  48. Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR (2001) The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 86(6):1586–1587

    CAS  PubMed  Google Scholar 

  49. von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L (2000) Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 16(4):815–824

    Google Scholar 

  50. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ et al (1981) Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 245(8):831–835

    Article  CAS  PubMed  Google Scholar 

  51. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR (1999) Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82(2):947–952

    CAS  PubMed  Google Scholar 

  52. Zhang J, Zhang YL, Ma KX, Qu JM (2013) Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax 68(5):442–450

    Article  PubMed  Google Scholar 

  53. Che DH, Cao JY, Shang LH, Man YC, Yu Y (2013) The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. Eur J Intern Med 24(5):433–439

    Article  CAS  PubMed  Google Scholar 

  54. Lecumberri R, Lopez Vivanco G, Font A, Gonzalez Billalabeitia E, Gurpide A, Gomez Codina J et al (2013) Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res 132(6):666–670

    Article  CAS  PubMed  Google Scholar 

  55. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR (2011) Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 29(15):2071–2076

    Article  PubMed  Google Scholar 

  56. Kahn SR (2006) The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis 21(1):41–48

    Article  PubMed  Google Scholar 

  57. Roberts LN, Patel RK, Donaldson N, Bonner L, Arya R (2014) Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis. Haematologica 99(3):e41–e43

    Article  PubMed  PubMed Central  Google Scholar 

  58. Hull RD, Pineo GF, Brant R, Liang J, Cook R, Solymoss S et al (2009) Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 122(8):762–769

    Article  PubMed  Google Scholar 

  59. Gonzalez-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta C (2008) Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: comparative study of enoxaparin versus coumarin. J Vasc Surg 48(4):953–959

    Article  PubMed  Google Scholar 

  60. Hull RD, Liang J, Townshend G (2011) Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 124(8):756–765

    Article  CAS  PubMed  Google Scholar 

  61. Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S et al (2013) Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost 11(2):270–281

    Article  CAS  PubMed  Google Scholar 

  62. Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P (2014) Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2:Cd001689

    PubMed  Google Scholar 

  63. Middeldorp S (2013) Thrombosis in women: what are the knowledge gaps in 2013? J Thromb Haemost 11(Suppl 1):180–191

    Article  PubMed  Google Scholar 

  64. Mousavi S, Moradi M, Khorshidahmad T, Motamedi M (2015) Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci 2015:507151. doi:10.1155/2015/507151

    PubMed  PubMed Central  Google Scholar 

  65. Sanford D, Naidu A, Alizadeh N, Lazo-Langner A (2014) The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials. J Thromb Haemost 12(7):1076–1085

    Article  CAS  PubMed  Google Scholar 

  66. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5(4):729–737

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vascular Surgery Department, Hospital da Beneficência Portuguesa de São Paulo, 925, Maestro Cardim St., São Paulo, São Paulo, Brazil

    Adilson Ferraz Paschoa

Authors
  1. Adilson Ferraz Paschoa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adilson Ferraz Paschoa.

Ethics declarations

Conflicts of interest

Adilson Ferraz Paschoa has received consulting and speaking fees. He is member of VTE Prophylaxis Sanofi Advisory Board. Publication support was provided by Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paschoa, A.F. Heparin: 100 years of pleiotropic effects. J Thromb Thrombolysis 41, 636–643 (2016). https://doi.org/10.1007/s11239-015-1261-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-015-1261-z

Keywords

Search

Navigation